NCT00445406View on ClinicalTrials.gov

Bevacizumab and Doxorubicin Hydrochloride Liposome in Treating Women With Locally Recurrent or Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

September 30, 2008

Study Completion Date

March 31, 2009

Conditions
Breast Cancer
Interventions
DRUG

bevacizumab + doxorubin hydrochloride liposme

Patients receive bevacizumab IV over 30-90 minutes and doxorubicin hydrochloride liposome IV over 30-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for up to 6 courses

DRUG

Bevacizumab

Patients then receive bevacizumab alone IV over 30-90 minutes on days 1 and 15. Courses with bevacizumab repeat every 4 weeks in the absence of disease progression or unacceptable toxicity

Trial Locations (1)

CH-4031

Universitaetsspital-Basel, Basel

All Listed Sponsors
lead

Swiss Cancer Institute

OTHER

NCT00445406 - Bevacizumab and Doxorubicin Hydrochloride Liposome in Treating Women With Locally Recurrent or Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter